0ABR.LSE H. Lundbeck A/S

Healthcare Drug Manufacturers - Specialty & Generic London Exchange
286.82 DKK
Close of Nov 3, 2026
31.60 50.70
Market cap
DKK 57.0B
P/E
21.9x
P/B
1.85x
ROE
20.9%
Dividend yield
1.65%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0ABR.LSE undervalued?

Graham number
Price286.82
Graham value213.68
Premium34.2%

0ABR.LSE trades 34.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

H. Lundbeck A/S fundamental analysis

No fundamental analysis for H. Lundbeck A/S yet.

H. Lundbeck A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About H. Lundbeck A/S

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Ci…

Full company profile